Loading…

Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure

Background Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) ra...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hypertension 2012-06, Vol.25 (6), p.690-696
Main Authors: Haller, Steven T., Kennedy, David J., Shidyak, Amjad, Budny, George V., Malhotra, Deepak, Fedorova, Olga V., Shapiro, Joseph I., Bagrov, Alexei Y.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3
cites cdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3
container_end_page 696
container_issue 6
container_start_page 690
container_title American journal of hypertension
container_volume 25
creator Haller, Steven T.
Kennedy, David J.
Shidyak, Amjad
Budny, George V.
Malhotra, Deepak
Fedorova, Olga V.
Shapiro, Joseph I.
Bagrov, Alexei Y.
description Background Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats. Methods In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery. Results In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced. Conclusions In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.
doi_str_mv 10.1038/ajh.2012.17
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3355226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1038/ajh.2012.17</oup_id><sourcerecordid>1015094089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</originalsourceid><addsrcrecordid>eNp9kc1r3DAQxUVpaLZpT70XQ2koFG81smzZl0IJ_Qik9NKexUiW1lq80layU_LfR85u049D0GEE8-PNvHmEvAC6Blq173A7rBkFtgbxiKyg41AKxurHZEXbri4FbeCUPE1pSynlTQNPyCljlWhpVa3I8DX4oMfgcSzQT06F_qbADTqfpmKH0fmgZosb450vork2MZlUaIy9Q11Yp2JILhVLE6dU_HLTUOghBu90xhdVi26co3lGTiyOyTw_1jPy49PH7xdfyqtvny8vPlyVmgs6lW3bWKY050YDFUzUive1bVibP5AfV0II2vYtUFSgVcMa3fTMql4w4DVWZ-T9QXc_q53ptfFTxFHuo8tubmRAJ__teDfITbiWVVXXjDVZ4M1RIIafs0mT3LmkzTiiN2FOEijUtOP5thl99R-6DXPMpu-oqmsZCMjU2wOl861SNPZ-GaBySVDmBOWSoASR6Zd_73_P_o4sA6-PACaNo43otUt_uLoT2cfCnR-4MO8fnHgL_VmxSg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013982171</pqid></control><display><type>article</type><title>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Haller, Steven T. ; Kennedy, David J. ; Shidyak, Amjad ; Budny, George V. ; Malhotra, Deepak ; Fedorova, Olga V. ; Shapiro, Joseph I. ; Bagrov, Alexei Y.</creator><creatorcontrib>Haller, Steven T. ; Kennedy, David J. ; Shidyak, Amjad ; Budny, George V. ; Malhotra, Deepak ; Fedorova, Olga V. ; Shapiro, Joseph I. ; Bagrov, Alexei Y.</creatorcontrib><description>Background Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats. Methods In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery. Results In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced. Conclusions In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>EISSN: 1879-1905</identifier><identifier>DOI: 10.1038/ajh.2012.17</identifier><identifier>PMID: 22378033</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Basingstoke: Oxford University Press</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Pressure - drug effects ; Blood Pressure - physiology ; Bufanolides - immunology ; Bufanolides - metabolism ; Cardiology. Vascular system ; Cardiomegaly - etiology ; Cardiomegaly - metabolism ; Cardiomegaly - prevention &amp; control ; Comorbidity ; Disease Models, Animal ; Experimental diseases ; Fibrosis ; Immunoglobulin Fab Fragments - pharmacology ; Immunoglobulin Fab Fragments - therapeutic use ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - metabolism ; Kidney Failure, Chronic - surgery ; Male ; Medical sciences ; Myocardium - metabolism ; Myocardium - pathology ; Nephrectomy ; Proto-Oncogene Protein c-fli-1 - metabolism ; Rats ; Rats, Sprague-Dawley</subject><ispartof>American journal of hypertension, 2012-06, Vol.25 (6), p.690-696</ispartof><rights>American Journal of Hypertension, Ltd. © 2012 by the American Journal of Hypertension, Ltd. 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jun 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</citedby><cites>FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25975223$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22378033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haller, Steven T.</creatorcontrib><creatorcontrib>Kennedy, David J.</creatorcontrib><creatorcontrib>Shidyak, Amjad</creatorcontrib><creatorcontrib>Budny, George V.</creatorcontrib><creatorcontrib>Malhotra, Deepak</creatorcontrib><creatorcontrib>Fedorova, Olga V.</creatorcontrib><creatorcontrib>Shapiro, Joseph I.</creatorcontrib><creatorcontrib>Bagrov, Alexei Y.</creatorcontrib><title>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</title><title>American journal of hypertension</title><addtitle>Am J Hypertens</addtitle><description>Background Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats. Methods In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery. Results In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced. Conclusions In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure - physiology</subject><subject>Bufanolides - immunology</subject><subject>Bufanolides - metabolism</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomegaly - etiology</subject><subject>Cardiomegaly - metabolism</subject><subject>Cardiomegaly - prevention &amp; control</subject><subject>Comorbidity</subject><subject>Disease Models, Animal</subject><subject>Experimental diseases</subject><subject>Fibrosis</subject><subject>Immunoglobulin Fab Fragments - pharmacology</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>Nephrectomy</subject><subject>Proto-Oncogene Protein c-fli-1 - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>0895-7061</issn><issn>1941-7225</issn><issn>1879-1905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kc1r3DAQxUVpaLZpT70XQ2koFG81smzZl0IJ_Qik9NKexUiW1lq80layU_LfR85u049D0GEE8-PNvHmEvAC6Blq173A7rBkFtgbxiKyg41AKxurHZEXbri4FbeCUPE1pSynlTQNPyCljlWhpVa3I8DX4oMfgcSzQT06F_qbADTqfpmKH0fmgZosb450vork2MZlUaIy9Q11Yp2JILhVLE6dU_HLTUOghBu90xhdVi26co3lGTiyOyTw_1jPy49PH7xdfyqtvny8vPlyVmgs6lW3bWKY050YDFUzUive1bVibP5AfV0II2vYtUFSgVcMa3fTMql4w4DVWZ-T9QXc_q53ptfFTxFHuo8tubmRAJ__teDfITbiWVVXXjDVZ4M1RIIafs0mT3LmkzTiiN2FOEijUtOP5thl99R-6DXPMpu-oqmsZCMjU2wOl861SNPZ-GaBySVDmBOWSoASR6Zd_73_P_o4sA6-PACaNo43otUt_uLoT2cfCnR-4MO8fnHgL_VmxSg</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Haller, Steven T.</creator><creator>Kennedy, David J.</creator><creator>Shidyak, Amjad</creator><creator>Budny, George V.</creator><creator>Malhotra, Deepak</creator><creator>Fedorova, Olga V.</creator><creator>Shapiro, Joseph I.</creator><creator>Bagrov, Alexei Y.</creator><general>Oxford University Press</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</title><author>Haller, Steven T. ; Kennedy, David J. ; Shidyak, Amjad ; Budny, George V. ; Malhotra, Deepak ; Fedorova, Olga V. ; Shapiro, Joseph I. ; Bagrov, Alexei Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure - physiology</topic><topic>Bufanolides - immunology</topic><topic>Bufanolides - metabolism</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomegaly - etiology</topic><topic>Cardiomegaly - metabolism</topic><topic>Cardiomegaly - prevention &amp; control</topic><topic>Comorbidity</topic><topic>Disease Models, Animal</topic><topic>Experimental diseases</topic><topic>Fibrosis</topic><topic>Immunoglobulin Fab Fragments - pharmacology</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>Nephrectomy</topic><topic>Proto-Oncogene Protein c-fli-1 - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haller, Steven T.</creatorcontrib><creatorcontrib>Kennedy, David J.</creatorcontrib><creatorcontrib>Shidyak, Amjad</creatorcontrib><creatorcontrib>Budny, George V.</creatorcontrib><creatorcontrib>Malhotra, Deepak</creatorcontrib><creatorcontrib>Fedorova, Olga V.</creatorcontrib><creatorcontrib>Shapiro, Joseph I.</creatorcontrib><creatorcontrib>Bagrov, Alexei Y.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haller, Steven T.</au><au>Kennedy, David J.</au><au>Shidyak, Amjad</au><au>Budny, George V.</au><au>Malhotra, Deepak</au><au>Fedorova, Olga V.</au><au>Shapiro, Joseph I.</au><au>Bagrov, Alexei Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure</atitle><jtitle>American journal of hypertension</jtitle><addtitle>Am J Hypertens</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>25</volume><issue>6</issue><spage>690</spage><epage>696</epage><pages>690-696</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><eissn>1879-1905</eissn><coden>AJHYE6</coden><abstract>Background Cardiotonic steroids (CTS) are implicated in pathophysiology of uremic cardiomyopathy. In the present study, we tested whether a monoclonal antibody (mAb) against the bufadienolide CTS, marinobufagenin (MBG), alleviates cardiac hypertrophy and fibrosis in partially nephrectomized (PNx) rats. Methods In PNx rats, we compared the effects of 3E9 anti-MBG mAb and of Digibind, an affinity-purified digoxin antibody, on blood pressure and cardiac hypertrophy and fibrosis following 4 weeks after the surgery. Results In PNx rats, a fourfold elevation in plasma MBG levels was associated with hypertension, increased cardiac levels of carbonylated protein, cardiac hypertrophy, a reduction in cardiac expression of a nuclear transcription factor which is a negative regulator of collagen synthesis, Friend leukemia integration-1 (Fli-1), and an increase in the levels of collagen-1. A single intraperitoneal administration of 3E9 mAb to PNx rats reduced blood pressure by 59 mm Hg for 7 days and produced a significant reduction in cardiac weight and cardiac levels of oxidative stress, an increase in the expression of Fli-1, and a reduction in cardiac fibrosis. The effects of Digibind were similar to those of 3E9 mAb, but were less pronounced. Conclusions In experimental chronic renal failure, elevated levels of MBG contribute to hypertension and induce cardiac fibrosis via suppression of Fli-1, representing a potential target for therapy.</abstract><cop>Basingstoke</cop><pub>Oxford University Press</pub><pmid>22378033</pmid><doi>10.1038/ajh.2012.17</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0895-7061
ispartof American journal of hypertension, 2012-06, Vol.25 (6), p.690-696
issn 0895-7061
1941-7225
1879-1905
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3355226
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
subjects Animals
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood Pressure - drug effects
Blood Pressure - physiology
Bufanolides - immunology
Bufanolides - metabolism
Cardiology. Vascular system
Cardiomegaly - etiology
Cardiomegaly - metabolism
Cardiomegaly - prevention & control
Comorbidity
Disease Models, Animal
Experimental diseases
Fibrosis
Immunoglobulin Fab Fragments - pharmacology
Immunoglobulin Fab Fragments - therapeutic use
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - metabolism
Kidney Failure, Chronic - surgery
Male
Medical sciences
Myocardium - metabolism
Myocardium - pathology
Nephrectomy
Proto-Oncogene Protein c-fli-1 - metabolism
Rats
Rats, Sprague-Dawley
title Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A10%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoclonal%20antibody%20against%20marinobufagenin%20reverses%20cardiac%20fibrosis%20in%20rats%20with%20chronic%20renal%20failure&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Haller,%20Steven%20T.&rft.date=2012-06-01&rft.volume=25&rft.issue=6&rft.spage=690&rft.epage=696&rft.pages=690-696&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1038/ajh.2012.17&rft_dat=%3Cproquest_pubme%3E1015094089%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-886f2bc44ec107275b4d5f6285b414144b77708d810ab1cb626c6d2fbd72145a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1013982171&rft_id=info:pmid/22378033&rft_oup_id=10.1038/ajh.2012.17&rfr_iscdi=true